These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 12604217)
1. Hydrogen bonding interactions between aldose reductase complexed with NADP(H) and inhibitor tolrestat studied by molecular dynamics simulations and binding assay. Lee YS; Hodoscek M; Kador PF; Sugiyama K Chem Biol Interact; 2003 Feb; 143-144():307-16. PubMed ID: 12604217 [TBL] [Abstract][Full Text] [Related]
2. Molecular dynamics simulations of the structure of aldose reductase complexed with the inhibitor tolrestat. Rastelli G; Costantino L Bioorg Med Chem Lett; 1998 Mar; 8(6):641-6. PubMed ID: 9871575 [TBL] [Abstract][Full Text] [Related]
3. Isolation of a non-covalent aldose reductase-nucleotide-inhibitor complex. Sugiyama K; Chen Z; Lee YS; Kador PF Biochem Pharmacol; 2000 Feb; 59(4):329-36. PubMed ID: 10644040 [TBL] [Abstract][Full Text] [Related]
4. Studies on the inhibitor-binding site of porcine aldehyde reductase: crystal structure of the holoenzyme-inhibitor ternary complex. el-Kabbani O; Carper DA; McGowan MH; Devedjiev Y; Rees-Milton KJ; Flynn TG Proteins; 1997 Oct; 29(2):186-92. PubMed ID: 9329083 [TBL] [Abstract][Full Text] [Related]
5. Mechanism of human aldehyde reductase: characterization of the active site pocket. Barski OA; Gabbay KH; Grimshaw CE; Bohren KM Biochemistry; 1995 Sep; 34(35):11264-75. PubMed ID: 7669785 [TBL] [Abstract][Full Text] [Related]
6. Correlation of binding constants and molecular modelling of inhibitors in the active sites of aldose reductase and aldehyde reductase. Carbone V; Zhao HT; Chung R; Endo S; Hara A; El-Kabbani O Bioorg Med Chem; 2009 Feb; 17(3):1244-50. PubMed ID: 19121944 [TBL] [Abstract][Full Text] [Related]
7. The crystallographic structure of the aldose reductase-IDD552 complex shows direct proton donation from tyrosine 48. Ruiz F; Hazemann I; Mitschler A; Joachimiak A; Schneider T; Karplus M; Podjarny A Acta Crystallogr D Biol Crystallogr; 2004 Aug; 60(Pt 8):1347-54. PubMed ID: 15272156 [TBL] [Abstract][Full Text] [Related]
8. A 'specificity' pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil. Urzhumtsev A; Tête-Favier F; Mitschler A; Barbanton J; Barth P; Urzhumtseva L; Biellmann JF; Podjarny A; Moras D Structure; 1997 May; 5(5):601-12. PubMed ID: 9195881 [TBL] [Abstract][Full Text] [Related]
9. Docking and molecular dynamics study on the inhibitory activity of coumarins on aldose reductase. Wang Z; Ling B; Zhang R; Liu Y J Phys Chem B; 2008 Aug; 112(32):10033-40. PubMed ID: 18637681 [TBL] [Abstract][Full Text] [Related]
10. Probing flexibility and "induced-fit" phenomena in aldose reductase by comparative crystal structure analysis and molecular dynamics simulations. Sotriffer CA; Krämer O; Klebe G Proteins; 2004 Jul; 56(1):52-66. PubMed ID: 15162486 [TBL] [Abstract][Full Text] [Related]
11. High-resolution crystal structure of aldose reductase complexed with the novel sulfonyl-pyridazinone inhibitor exhibiting an alternative active site anchoring group. Steuber H; Zentgraf M; Podjarny A; Heine A; Klebe G J Mol Biol; 2006 Feb; 356(1):45-56. PubMed ID: 16337231 [TBL] [Abstract][Full Text] [Related]
12. Human aldose reductase: pK of tyrosine 48 reveals the preferred ionization state for catalysis and inhibition. Grimshaw CE; Bohren KM; Lai CJ; Gabbay KH Biochemistry; 1995 Nov; 34(44):14374-84. PubMed ID: 7578041 [TBL] [Abstract][Full Text] [Related]
13. Induced fit docking, pharmacophore modeling, and molecular dynamic simulations on thiazolidinedione derivatives to explore key interactions with Tyr48 in polyol pathway. Vijjulatha M; Lingala Y; Merugu RT J Mol Model; 2014 Jul; 20(7):2348. PubMed ID: 24974084 [TBL] [Abstract][Full Text] [Related]
14. Nitrophenyl derivatives as aldose reductase inhibitors. Costantino L; Ferrari AM; Gamberini MC; Rastelli G Bioorg Med Chem; 2002 Dec; 10(12):3923-31. PubMed ID: 12413844 [TBL] [Abstract][Full Text] [Related]
15. X-ray structure of the V301L aldo-keto reductase 1B10 complexed with NADP(+) and the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity. Ruiz FX; Cousido-Siah A; Mitschler A; Farrés J; Parés X; Podjarny A Chem Biol Interact; 2013 Feb; 202(1-3):178-85. PubMed ID: 23295227 [TBL] [Abstract][Full Text] [Related]
16. Docking and molecular dynamics studies toward the binding of new natural phenolic marine inhibitors and aldose reductase. Wang Z; Ling B; Zhang R; Suo Y; Liu Y; Yu Z; Liu C J Mol Graph Model; 2009 Sep; 28(2):162-9. PubMed ID: 19616461 [TBL] [Abstract][Full Text] [Related]
17. Rotamers of tolrestat and their binding mode to aldose reductase. Lee YS; Sugiyama K; Kador PF Adv Exp Med Biol; 1999; 463():465-72. PubMed ID: 10352720 [No Abstract] [Full Text] [Related]
18. Novel insights into the structural requirements for the design of selective and specific aldose reductase inhibitors. Kumar H; Shah A; Sobhia ME J Mol Model; 2012 May; 18(5):1791-9. PubMed ID: 21833829 [TBL] [Abstract][Full Text] [Related]
19. Ultrahigh resolution drug design. II. Atomic resolution structures of human aldose reductase holoenzyme complexed with Fidarestat and Minalrestat: implications for the binding of cyclic imide inhibitors. El-Kabbani O; Darmanin C; Schneider TR; Hazemann I; Ruiz F; Oka M; Joachimiak A; Schulze-Briese C; Tomizaki T; Mitschler A; Podjarny A Proteins; 2004 Jun; 55(4):805-13. PubMed ID: 15146479 [TBL] [Abstract][Full Text] [Related]
20. In vitro studies of potent aldose reductase inhibitors: Synthesis, characterization, biological evaluation and docking analysis of rhodanine-3-hippuric acid derivatives. Celestina SK; Sundaram K; Ravi S Bioorg Chem; 2020 Apr; 97():103640. PubMed ID: 32086051 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]